Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
This important cross-species study tests whether the corpus callosum contains parallel, segregated pathways for ipsilateral and contralateral visual-field information, rather than mixed inputs from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results